Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $255,360.00 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, January 13th. The stock was sold at an average price of $18.24, for a total transaction of $255,360.00. Following the sale, the chief operating officer now directly owns 88,975 shares of the company’s stock, valued at approximately $1,622,904. This trade represents a 13.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Kiniksa Pharmaceuticals Stock Performance

KNSA opened at $18.54 on Friday. Kiniksa Pharmaceuticals, Ltd. has a one year low of $16.56 and a one year high of $28.15. The stock has a market capitalization of $1.34 billion, a P/E ratio of -132.42 and a beta of 0.29. The business’s 50-day simple moving average is $20.67 and its 200-day simple moving average is $23.21.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The firm had revenue of $112.21 million during the quarter, compared to analysts’ expectations of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s quarterly revenue was up 67.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.20) EPS. On average, equities research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Institutional Trading of Kiniksa Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Wellington Management Group LLP purchased a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at about $1,192,000. Dimensional Fund Advisors LP lifted its position in Kiniksa Pharmaceuticals by 31.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock worth $12,398,000 after acquiring an additional 157,741 shares during the period. Segall Bryant & Hamill LLC purchased a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $675,000. Parkman Healthcare Partners LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 16.7% in the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock valued at $18,874,000 after purchasing an additional 108,102 shares during the period. Finally, Millennium Management LLC raised its stake in shares of Kiniksa Pharmaceuticals by 159.8% during the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after purchasing an additional 382,539 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on KNSA. Evercore ISI lifted their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. boosted their target price on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Wedbush reiterated an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $36.60.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.